WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics

Psychopharmacology

Volumn 204, Issue 1, 2009, Pages 37-48

  Grauer, Steven M ^a   Graf, Radka ^a   Navarra, Rachel ^a   Sung, Amy ^a   Logue, Sheree F ^a   Stack, Gary ^a   Huselton, Christine ^a   Liu, Zhi ^a   Comery, Thomas A ^a   Marquis, Karen L ^a   Rosenzweig Lipson, Sharon ^a  

^a PFIZER INC   (United States)

Author keywords

5 HT2C agonist; Antipsychotics; Co administration; Preclinical efficacy; Rodents; Side effects

Indexed keywords

1,2,3,4,8,9,10,10A OCTAHYDRO 7BH CYCLOPENTA[B][1,4]DIAZEPINO[6,7,1 HI]INDOLE; APOMORPHINE; CLOZAPINE; DIZOCILPINE; DOPAMINE; HALOPERIDOL; SEROTONIN 2C AGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AVOIDANCE BEHAVIOR; CATALEPSY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; EXTRAPYRAMIDAL SYMPTOM; MALE; MESOLIMBIC DOPAMINERGIC SYSTEM; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; STARTLE REFLEX; STEREOTYPY; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; AVOIDANCE LEARNING; AZEPINES; CATALEPSY; CLOZAPINE; DIZOCILPINE MALEATE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HALOPERIDOL; INDOLES; MALE; MICE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2C; STARTLE REACTION; STEREOTYPED BEHAVIOR;

EID: 67349201388     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-008-1433-z     Document Type: Article

References (42)

1. DB Allison JL Mentore H Mooseong LP Chander JC Cappelleri MC Infante PJ Weiden 1999 Antipsychotic-induced weight gain: a comprehensive research synthesis Am J Psychiatry 156 1686 1696 (Pubitemid 29517559)
2. D Antai-Otong 2004 Metabolic effects associated with atypical antipsychotic medications Perspectives in Psychiatric Care 40 70 72 (Pubitemid 39091372)
3. J Arnt 1982 Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade Acta Pharmacol Toxicol 51 321 329
4. T Baptista S De Mendoza S Beaulieu 2004 The metabolic syndrome during atypical antipsychotic drug treatment: mechanism and management Metabolic Syndrome and Related Disorders 2 290 307 (Pubitemid 40846902)
5. 3 receptor antagonists thioperamide and ciproxifan Behav Brain Res 153 69 76 (Pubitemid 38829290)
6. A Buchanan 1992 A two-year prospective study of treatment compliance in patients with schizophrenia Psychol Med 22 787 797
7. DE Casey 1996 Side effects of new antipsychotic agents J Clin Psych 57 Suppl s40 s45 (Pubitemid 26389785)
8. JT Coyle G Tsai D Goff 2003 Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia Ann NY Acad Sci 1003 318 327 (Pubitemid 38083065)
9. B Costall RJ Naylor Neumeyer 1975 Differences in the nature of stereotyped behaviour induced by apomorphine derivatives in the rat and in their actions in extrapyramidal and mesolimbic brain areas Eur J Pharmacol 31 1 16
10. B Costall RJ Naylor V Nohria 1980 On the importance of mesolimbic mechanisms for the control of apomorphine induced climbing behaviour in the mouse Br J Pharmacol 68 175P 176P
11. PJ Cowen PA Sargent C Williams EM Goodall AB Orlikov 1995 Hypophagic, endocrine and subjective responses to m-chlorophenylpiperazine in healthy men and women Hum Psychopharmacol 10 385 391
12. P Czobor J Volavka B Sheitman JP Lindenmayer L Citrome J [tmp] McEvoy TB Cooper M Chakos JA Lieberman 2002 Antipsychotic-induced weight gain and therapeutic response: a differential association J Clin Pyschopharmacol 22 244 251 (Pubitemid 34546838)
13. 2B receptor agonists: a combined in vivo electrophysiological and microdialysis study Synapse 35 53 61
14. 2C receptor-selective agonist with anorectic activity J Pharmacol Exp Ther 313 862 869 (Pubitemid 40604189)
15. J Dunlop K Marquis HK Lim L Leung J Kao C Cheesman Rosenzweig-Lipson 2006 Pharmacological profile of the 5-HT2C receptor agonist WAY-163909; therapeutic potential in multiple indications CNS Drug Reviews 12 3 167 176 (Pubitemid 46047786)
16. J Gerlach 1999 The continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment J Clin Psychiatry 60 Suppl s20 s23 (Pubitemid 30021737)
17. M Gervin J Browne M Garavan C Roe C Larkin O Callaghan 1999 Dysphoric subjective response to antipsychotics in schizophrenia: relationship to extrapyramidal side-effects and symptomatology Eur Psychiatry 14 405 409
18. MA Geyer K Krebs-Thomson DL Braff NR Swerdlow 2001 Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenics: as decade in review Psychopharmacology 156 117 154 (Pubitemid 32702206)
19. SD Gleason HE Shannon 1997 Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice Psychopharmacology 129 79 84 (Pubitemid 27037454)
20. DC Goff L Sullivan JP [tmp] McEvoy JM Meyer HA Nasrallah GL Daumit S Lamberti RB D'Agostino TS Stroup S Davis JA Lieberman 2005 A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls Schizophr Res 80 1 45 53 (Pubitemid 41587462)
21. DC Hoffman H Donovan 1995 Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability Psychopharmacology 120 128 133
22. S Kapur G Remington 2001 Aytpical antipsychotics: new directions and challenges in the treatment of schizophrenia Annu Rev Med 52 503 517 (Pubitemid 32195338)
23. J Kane MG Woerner J Lieberman 1998 Tardive dyskinesia: prevalence, incidence and risk factors J Clin Psychopharmacol 8 52S 62S
24. CE Koro DO Fedder GJ L'Italien SS Weiss LS Magder J Kreyenbuhl DA Rivicki RW Buchanan 2002 Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study BMJ 325 243 245
25. 2 receptors Curr Drug Targ CNS Neurolog Disord 3 11 26 (Pubitemid 38854898)
26. JA Lieberman TS Stroup JP [tmp] McEvoy 2005 Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 353 12 1209 1223 (Pubitemid 41345943)
27. KL Marquis AL Sabb SF Logue JA Brennan MJ Piesla TA Comery SM Grauer CR Ashby Jr HQ Nguyen LA Dawson JE Barrett G Stack HY Meltzer BL Harrison S Rosenzweig-Lipson 2007 WAY-163909 ((7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH- cyclopenta-[b][1,4]diazepino[6,7,1hi]indole): a novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity J Pharmacol Exp Ther 320 486 496 (Pubitemid 46025760)
28. JP [tmp] McEvoy JM Meyer HA Nasrallah SM Davis L Sullivan HY Meltzer J Hsiao TS Stroup JA Lieberman 2005 Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparisons with national estimates from NHANES III Schizophr Res 80 1 19 32 (Pubitemid 41587460)
29. HY Meltzer 2004 What's atypical about atypical antipsychotic drugs Curr Op in Pharmacol 4 53 57 (Pubitemid 38145838)
30. JM Meyer 2001 Effects of atypical antipsychotics on weight and serum lipid levels J Clin Psychiatry 62 Suppl s27 s41 (Pubitemid 34052254)
31. 2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA) but not 5-HT release in the frontal cortex in vivo Neuropharmacol 37 953 955 (Pubitemid 28375762)
32. S Navailles P De Deurwaerdere U Spampinato 2006 Clozapine and haloperidol differentially alter the constitutive activity of central serotonin2C receptors in vivo Biological Psychiatry. 59 6 568 575 (Pubitemid 43320546)
33. 2C receptor gene Nat Med 4 10 1152 1156 (Pubitemid 28468828)
34. SM Roger SM [tmp] McCann SH Kennedy 2001 Antipsychotic metabolic effects: diabetes mellitus and lipid abnormalities Can J Psychiatry 46 273 280 (Pubitemid 32423994)
35. D Robinson MG Woerner JM Alvir R Bilder R Goldman S Geisler A Koreen B Sheitman M Chakos D Mayerhoff JA Lieberman 1999 Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder Arch Gen Psych 56 241 247 (Pubitemid 29125132)
36. 2C receptor agonist WAY-161505 Brain Res 1073-1074 240 251 (Pubitemid 44648072)
37. S Rosenzweig-Lipson A Sabb G Stack P Mitchell I Lucki J Malberg S Grauer J Brennan JF Cryan SJS Rizzo J Dunlop JE Barrett KL Marquis 2007 Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents Psychopharmacology 192 2 159 170 (Pubitemid 46669211)
38. CS Shilliam LA Dawson 2005 The effect of clozapine on extracellular dopamine levels in the shell subregion of the rat nucleus accumbens is reversed following chronic administration: comparison with a selective 5-HT(2C) receptor antagonist Neuropsychopharmacol 30 372 380 (Pubitemid 40129488)
39. DM Taylor R [tmp] McAskill 2000 Atypical antipsychotics and weight gain-a systematic review Acta Psychiatrica Scandinavica 101 416 432 (Pubitemid 30365564)
40. LF Van Gaal 2006 Long-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposity Eur Neuropsychopharmacol 16 S142 S148 (Pubitemid 44177766)
41. T Van Putten 1974 Why do schizophrenic patients refuse to take their drugs Arch Gen Psych 31 67 72
42. JL Young HV Zonana L Shepler 1986 Medication non-compliance in schizophrenia: codification and update Bull Am Acad Psych Law 14 105 122 (Pubitemid 17222209)